ArticleNature chemical biology2020
Prospecting for molecular glues.
Article in Nature chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolution and impact of molecular glue research: a bibliometric analysis from 2000 to 2023.Frontiers in oncology · 2024Pooled it
- Article
- New approaches for challenging therapeutic targets.Drug discovery today · 2024Review
- C2H2 Zinc Finger Transcription Factors Associated with Hemoglobinopathies.Journal of molecular biology · 2024Review
- Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation.Cancers · 2024Review
- Functional Classification of Fusion Proteins in Sarcoma.Cancers · 2024Review
- Direct-to-biology, automated, nano-scale synthesis, and phenotypic screening-enabled E3 ligase modulator discovery.Nature communications · 2023Article
- Expanding PROTACtable genome universe of E3 ligases.Nature communications · 2023Article
- Review
- Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.Signal transduction and targeted therapy · 2023Review
- E3 ubiquitin ligase on the biological properties of hematopoietic stem cell.Journal of molecular medicine (Berlin, Germany) · 2023Review
- Emerging approaches to CDK inhibitor development, a structural perspective.RSC chemical biology · 2023Article
- Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic.Biochemistry · 2023Review
- Seeing the forest through the trees: characterizing the glycoproteome.Trends in biochemical sciences · 2022Review
- Anti-HER2 therapy in metastatic breast cancer: many choices and future directions.Cancer metastasis reviews · 2022Review
- Review
- Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase.Cancers · 2021Review
- Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.European journal of medicinal chemistry · 2021Article
- From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation.Frontiers in chemistry · 2021Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32747810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.